Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Rhea-AI Summary

Biodesix (Nasdaq: BDSX) announced poster presentations of new clinical and development data at two scientific meetings in December 2025. At NACLC (Dec 5–7, Chicago) the company will present post‑market Nodify Lung® data that address timely lung nodule risk classification and modeling of autoantibody testing impact on time to lung cancer diagnosis. At SABCS (Dec 9–12, San Antonio) Biodesix will present development data for an ultra‑sensitive ESR1 droplet digital PCR test for detecting and monitoring ESR1 variants in HR+/HER2‑ advanced breast cancer; the test is offered to biopharmaceutical customers via Development Services. The company also received two recognitions at ISPOR Europe 2025 for research on pulmonary nodule follow‑up and related healthcare costs, to be published in the December supplement of Value in Health.

Clinical utility data for Nodify Lung^® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer

Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS)

LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.

At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago, IL, Biodesix will present new findings on its on-market Nodify Lung^® tests, with data that spotlight the importance of timely, accurate lung nodule risk classification to support the early detection of lung cancer:

• Refining Post-test Probability of Lung Cancer Using Post-Market Data from a Blood-based Biomarker Test in Pulmonary Nodule Patients.
  Authors: Michael N. Kammer, PhD (Biodesix Head of Radiomics and Presenter); Trevor Pitcher, PhD; Gary Pestano, PhD; Laura Peek, PhD; James R. Jett, MD, MS, FCCP; Steven C. Springmeyer, MD, FCCP.

• Modeling the Impact of an Autoantibody Blood Test for Lung Cancer on Time to Diagnosis in Pulmonary Nodule Assessment: A Multi-Cohort Analysis.
  Authors: Kathryn Long, MD (Presenter); Gerard A. Silvestri, MD, MS, Master FCCP; Michael N. Kammer, PhD; Trevor Pitcher, PhD; James Jett, MD; Viswam S. Nair, MD.

The company will also present data on the development of a new ultra-sensitive ESR1 test for initial detection and monitoring of the mutations in HR+/HER2- advanced breast cancers at the San Antonio Breast Cancer Symposium, December 9 -12, San Antonio, TX. This innovative test is now available to biopharmaceutical customers as part of the company’s Development Services offering:

• Poster Session 4, PS4-02-29: Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1 variants in liquid biopsies.
  Authors: Leisa Jackson (Biodesix Staff Scientist and Presenter), Helen Halpin, and Gary Pestano, PhD.

In addition, at the recent International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025 Meeting in November, Biodesix was awarded two distinguished recognitions: a Best General Poster Research Presentation and a Top 5% Research Certificate. The presented research highlighted the significant healthcare costs associated with pulmonary nodules and the widespread lack of appropriate follow-up. These gaps in nodule surveillance contribute to delayed diagnoses and increased downstream clinical and economic burden. ISPOR will publish all award-winning research in their December 2025 conference supplement issue of Value in Health.

• PT5: Pulmonary Nodule (PN)-Related and Lung Cancer-Related Workup Costs Within the Two-Year Period After Diagnosis of a PN in the United States
  Author: Kimberly Le, MBA, MS, PharmD (Biodesix Director of HEOR and Presenter).

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung^® Nodule Risk Assessment and IQLung^® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843

FAQ

What data will Biodesix (BDSX) present at NACLC Dec 5–7, 2025?

Biodesix will present post‑market Nodify Lung® data on refining post‑test lung cancer probability and a multi‑cohort model of autoantibody testing impact on time to diagnosis.

When and where will Biodesix present the ultra‑sensitive ESR1 assay for breast cancer (BDSX)?

Biodesix will present the ESR1 droplet digital PCR development data at SABCS, Dec 9–12, 2025 in San Antonio, TX.

Is the new ultra‑sensitive ESR1 test from Biodesix available to customers (BDSX)?

Yes; the ESR1 assay is available to biopharmaceutical customers through Biodesix Development Services.

What recognitions did Biodesix (BDSX) receive at ISPOR Europe 2025?

Biodesix received a Best General Poster Research Presentation and a Top 5% Research Certificate for pulmonary nodule cost and follow‑up research.

How do the NACLC Nodify Lung® findings relate to lung cancer diagnosis timing (BDSX)?

The presented Nodify Lung® post‑market analyses focus on improving risk classification to support earlier detection and inform nodule follow‑up.